Statistical treatment of withdrawal in trials of anti-dementia drugs

The Lancet

Volumn 372, Issue 9647, 2008, Pages 1382-1383

  Mackinnon, Andrew ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIMEBON;

ALZHEIMER DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; COMORBIDITY; DRUG WITHDRAWAL; HUMAN; LETTER; MENTAL DETERIORATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 53749094427     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61581-0     Document Type: Letter

References (5)

1. Doody R.S., Gavrilova S.I., Sano M., et al., on behalf of the dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372 (2008) 207-215
2. Burns A., and Jacoby R. Dimebon in Alzheimer's disease: old drug for new indication. Lancet 372 (2008) 179-180
3. Lavori P.W. Clinical trials in psychiatry: should protocol deviation censor patient data?. Neuropsychopharmacology 6 (1992) 39-48
4. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient-I: introduction and design. Br J Cancer 34 (1976) 585-612
5. Thomas R.G., Berg J.D., Sano M., and Thal L. Analysis of longitudinal data in an Alzheimer's disease clinical trial. Stat Med 19 (2000) 1433-1440